Skip to main content
Top

21-04-2024 | Insulinoma | Case Report Free for a limited time

A case of insulinoma misidentified as schizophrenia due to its manifestation in neuropsychiatric symptoms

Authors: Tomoyuki Haba, Kengo Yamakawa, Sayako Ozeki, Akira Sumida, Takehiro Kato, Eiji Kuroda, Takako Maruyama, Takaaki Murakami, Daisuke Yabe

Published in: Diabetology International

Login to get access

Abstract

Insulinomas can present with neuroglycopenic symptoms suggesting neuropsychiatric disorders, delaying diagnosis and treatment. We recently treated a 65-year-old woman with insulinoma who was misdiagnosed at her nearby psychiatric clinic as having schizophrenia because of personality changes and memory impairment; she was treated with brexpiprazole, which was discontinued due to persistence of the symptoms. Despite her relatively low casual plasma glucose (70 mg/dL), the physician at the psychiatric clinic did not investigate the possibility of hypoglycemia, partly because her HbA1c level (5.2%) was within normal range. After skipping lunch one day, she was found by her family to be unable to communicate properly. She was transported to the emergency room of our hospital, where intermittently scanning continuous glucose monitoring (isCGM) use permitted detection of the hypoglycemia and led to a diagnosis of insulinoma and successful resection. A 72-h fasting test established hyperinsulinemic hypoglycemia. Contrast-enhanced computed-tomography and endoscopic ultrasonography together with selective arterial calcium stimulation test revealed an insulin-secreting tumor in the tail of the pancreas. Surgical resection of the tumor corrected her glucose and insulin levels as well as eliminated the insulinoma neuropsychiatric symptoms. Pathological examination showed that the tumor was positive for chromogranin A, synaptophysin and insulin. It is, therefore, important for physicians to be aware that insulinomas can manifest as neuroglycopenic symptoms and to consider the possibility of hypoglycemia by careful medical interview and isCGM, especially when patients suspected of psychiatric disorders do not show the expected response to antipsychotic drugs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hofland J, Kaltsas G, de Herder WW. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev. 2020;41:371–403.CrossRefPubMedPubMedCentral Hofland J, Kaltsas G, de Herder WW. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev. 2020;41:371–403.CrossRefPubMedPubMedCentral
2.
go back to reference Masui T, Ito T, Komoto I, et al. Nationwide registry for patients with neuroendocrine neoplasm of pancreas, gastrointestinal tract, lungs, bronchi, or thymus in Japan. Int J Clin Oncol. 2022;27:840–9.CrossRefPubMedPubMedCentral Masui T, Ito T, Komoto I, et al. Nationwide registry for patients with neuroendocrine neoplasm of pancreas, gastrointestinal tract, lungs, bronchi, or thymus in Japan. Int J Clin Oncol. 2022;27:840–9.CrossRefPubMedPubMedCentral
3.
go back to reference de Herder WW, Rehfeld JF, Kidd M, Modlin IM. A short history of neuroendocrine tumours and their peptide hormones. Best Pract Res Clin Endocrinol Metab. 2016;30:3–17.CrossRefPubMed de Herder WW, Rehfeld JF, Kidd M, Modlin IM. A short history of neuroendocrine tumours and their peptide hormones. Best Pract Res Clin Endocrinol Metab. 2016;30:3–17.CrossRefPubMed
5.
go back to reference Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol. 1991;260:E67–74.PubMed Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol. 1991;260:E67–74.PubMed
6.
go back to reference Ding Y, Wang S, Liu J, Yang Y, Liu Z, et al. Neuropsychiatric profiles of patients with insulinomas. Eur Neurol. 2010;63:48–51.CrossRefPubMed Ding Y, Wang S, Liu J, Yang Y, Liu Z, et al. Neuropsychiatric profiles of patients with insulinomas. Eur Neurol. 2010;63:48–51.CrossRefPubMed
7.
go back to reference Murakami T, Yamashita T, Yabe D, et al. Insulinoma with a history of epilepsy: still a possible misleading factor in the early diagnosis of insulinoma. Intern Med. 2017;56:3199–204.CrossRefPubMedPubMedCentral Murakami T, Yamashita T, Yabe D, et al. Insulinoma with a history of epilepsy: still a possible misleading factor in the early diagnosis of insulinoma. Intern Med. 2017;56:3199–204.CrossRefPubMedPubMedCentral
8.
go back to reference Munir A, Choudhary P, Harrison B, Heller S, Newell-Price J. Continuous glucose monitoring in patients with insulinoma. Clin Endocrinol. 2018;68:912–8.CrossRef Munir A, Choudhary P, Harrison B, Heller S, Newell-Price J. Continuous glucose monitoring in patients with insulinoma. Clin Endocrinol. 2018;68:912–8.CrossRef
11.
go back to reference Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med. 1999;106:307–10.CrossRefPubMed Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med. 1999;106:307–10.CrossRefPubMed
12.
go back to reference Imamura M, Nakamoto Y, Uose S, Komoto I, Awane M, et al. Diagnosis of functioning pancreaticoduodenal neuroendocrine tumors. J Hepatobiliary Pancreat Sci. 2015;22:602–9.CrossRefPubMed Imamura M, Nakamoto Y, Uose S, Komoto I, Awane M, et al. Diagnosis of functioning pancreaticoduodenal neuroendocrine tumors. J Hepatobiliary Pancreat Sci. 2015;22:602–9.CrossRefPubMed
13.
go back to reference Dai H, Chen H, Hong X, Han X, Xu Q, et al. Early detection of cognitive impairment in patients with insulinoma. Endocrine. 2019;65:524–30.CrossRefPubMed Dai H, Chen H, Hong X, Han X, Xu Q, et al. Early detection of cognitive impairment in patients with insulinoma. Endocrine. 2019;65:524–30.CrossRefPubMed
14.
go back to reference Moser O, Eckstein ML, McCarthy O, Deere R, Pitt J, et al. Performance of the freestyle libre flash glucose monitoring (flash GM) system in individuals with type 1 diabetes: a secondary outcome analysis of a randomized crossover trial. Diabetes Obes Metab. 2019;21:2505–12.CrossRefPubMedPubMedCentral Moser O, Eckstein ML, McCarthy O, Deere R, Pitt J, et al. Performance of the freestyle libre flash glucose monitoring (flash GM) system in individuals with type 1 diabetes: a secondary outcome analysis of a randomized crossover trial. Diabetes Obes Metab. 2019;21:2505–12.CrossRefPubMedPubMedCentral
15.
go back to reference Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M, et al. Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals (Basel). 2021;14:238.CrossRefPubMed Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M, et al. Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals (Basel). 2021;14:238.CrossRefPubMed
16.
go back to reference Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin. Nature. 1995;374:542–6.CrossRefPubMed Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin. Nature. 1995;374:542–6.CrossRefPubMed
17.
go back to reference Orthen-Gambill N, Salomon M. Differential effects of psychotropic drugs on feeding in rats: is histamine blockade involved? Pharmacol Biochem Behav. 1990;36:837–41.CrossRefPubMed Orthen-Gambill N, Salomon M. Differential effects of psychotropic drugs on feeding in rats: is histamine blockade involved? Pharmacol Biochem Behav. 1990;36:837–41.CrossRefPubMed
18.
go back to reference Weston-Green K, Huang XF, Lian J, et al. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol. 2012;22:364–73.CrossRefPubMed Weston-Green K, Huang XF, Lian J, et al. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol. 2012;22:364–73.CrossRefPubMed
19.
go back to reference Yamamoto N, Oh E, Nishiyama K, Yoshida M, Saeki A, et al. Case of insulinoma manifesting as hyperinsulinemia after discontinuing quetiapine in an elderly patient with delirium. Geriatr Gerontol Int. 2017;17:849–51.CrossRefPubMed Yamamoto N, Oh E, Nishiyama K, Yoshida M, Saeki A, et al. Case of insulinoma manifesting as hyperinsulinemia after discontinuing quetiapine in an elderly patient with delirium. Geriatr Gerontol Int. 2017;17:849–51.CrossRefPubMed
20.
go back to reference Suzuki M, Niidome K, Maeda K, Kikuchi T, Usami T, et al. Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI Tablets 1mg, 2mg). Nihon Yakurigaku Zasshi. 2019;154:275–87.CrossRefPubMed Suzuki M, Niidome K, Maeda K, Kikuchi T, Usami T, et al. Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI Tablets 1mg, 2mg). Nihon Yakurigaku Zasshi. 2019;154:275–87.CrossRefPubMed
Metadata
Title
A case of insulinoma misidentified as schizophrenia due to its manifestation in neuropsychiatric symptoms
Authors
Tomoyuki Haba
Kengo Yamakawa
Sayako Ozeki
Akira Sumida
Takehiro Kato
Eiji Kuroda
Takako Maruyama
Takaaki Murakami
Daisuke Yabe
Publication date
21-04-2024
Publisher
Springer Nature Singapore
Published in
Diabetology International
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-024-00722-9